Royals set to join ADI’s 36th International Conference
ADI is pleased to welcome both Her Majesty The Queen Sofía of Spain and Her Royal Highness Princess Muna Al Hussein of Jordan to ADI’s 36th International Conference
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
ADI is pleased to welcome both Her Majesty The Queen Sofía of Spain and Her Royal Highness Princess Muna Al Hussein of Jordan to ADI’s 36th International Conference
AD-RIDDLE, funded by the Innovative Health Initiative, a European Union public privative partnership, brings together academics, healthcare providers, pharmaceutical companies, regulatory bodies to develop tools and resources for healthcare providers.
The project, launching 1 September, will aim to raise funds for ADI through the sale of a collection of photographs in the form of NFTs.
DY Suharya, ADI Regional director for Asia Pacific, will lead on a Values 20 (V20) work stream in preparation for the G20 summit, taking place on 15-16 November 2022.
If you are living with dementia, a carer, clinician, formal (paid) health or long-term care practitioner, we need to hear about your experience of post-diagnosis for the World Alzheimer Report 2022.
ADI is pleased to announce the formalisation of a long-standing collaboration with World Wide-FINGERS (WW-FINGERS) by joining in partnership to reduce the risk of dementia worldwide.
ADI delivered important statements to the World Health Organization (WHO) and Member States on the importance of considering those living with dementia and carers in pandemic responses, humanitarian crises, as well as a new neurological global action plan.
The Centers for Medicare & Medicaid Services (CMS) in the US confirms requirement for clinical trials to access Aduhelm but broadens which trials are eligible.
The study by Institute for Health Metrics and Evaluation (IHME) published in The Lancet predicts 153 million people will be living with Alzheimer’s disease by 2050.
This follows the result of the negative vote trend by the Committee for Medicinal Products for Human Use (CHMP) at their oral explanation meeting in November.